EP2968246A4 - Compositions d'acide pentanoïque oméga 3 et méthodes d'utilisation - Google Patents

Compositions d'acide pentanoïque oméga 3 et méthodes d'utilisation

Info

Publication number
EP2968246A4
EP2968246A4 EP13878433.5A EP13878433A EP2968246A4 EP 2968246 A4 EP2968246 A4 EP 2968246A4 EP 13878433 A EP13878433 A EP 13878433A EP 2968246 A4 EP2968246 A4 EP 2968246A4
Authority
EP
European Patent Office
Prior art keywords
omega
methods
acid compositions
pentaenoic acid
pentaenoic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13878433.5A
Other languages
German (de)
English (en)
Other versions
EP2968246A1 (fr
Inventor
Abdel Aziz Fawzy
George Bobotas
Roelof Rongen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Matinas Biopharma Inc
Original Assignee
Matinas Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matinas Biopharma Inc filed Critical Matinas Biopharma Inc
Publication of EP2968246A1 publication Critical patent/EP2968246A1/fr
Publication of EP2968246A4 publication Critical patent/EP2968246A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Edible Oils And Fats (AREA)
EP13878433.5A 2013-03-13 2013-12-17 Compositions d'acide pentanoïque oméga 3 et méthodes d'utilisation Withdrawn EP2968246A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361780948P 2013-03-13 2013-03-13
PCT/US2013/075661 WO2014143272A1 (fr) 2013-03-13 2013-12-17 Compositions d'acide pentanoïque oméga 3 et méthodes d'utilisation

Publications (2)

Publication Number Publication Date
EP2968246A1 EP2968246A1 (fr) 2016-01-20
EP2968246A4 true EP2968246A4 (fr) 2016-08-03

Family

ID=51537458

Family Applications (2)

Application Number Title Priority Date Filing Date
EP13878433.5A Withdrawn EP2968246A4 (fr) 2013-03-13 2013-12-17 Compositions d'acide pentanoïque oméga 3 et méthodes d'utilisation
EP14779339.2A Withdrawn EP2986148A2 (fr) 2013-03-13 2014-03-12 Compositions comprenant de l'acide docosapentaénoïque et procédés d'utilisation

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP14779339.2A Withdrawn EP2986148A2 (fr) 2013-03-13 2014-03-12 Compositions comprenant de l'acide docosapentaénoïque et procédés d'utilisation

Country Status (4)

Country Link
EP (2) EP2968246A4 (fr)
JP (2) JP2016518315A (fr)
CA (2) CA2905671A1 (fr)
WO (4) WO2014143275A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170093966A (ko) * 2014-12-15 2017-08-16 디에스엠 아이피 어셋츠 비.브이. 비-알콜성 지방간 질환의 치료
WO2017193563A1 (fr) * 2015-11-13 2017-11-16 深圳君圣泰生物技术有限公司 Composition, et application et préparation pharmaceutique de cette dernière
CN116492339A (zh) * 2015-11-13 2023-07-28 深圳君圣泰生物技术有限公司 一种组合物及其用途、药物制剂
KR20190113520A (ko) * 2017-02-09 2019-10-08 에스.엘.에이. 파르마 에이지 유리지방산으로서 고도로 정제된 에이코사펜타엔산의 궤양성 대장염 환자의 분변 칼프로텍틴 레벨의 감소 및 임상 재발 방지
CN107006809B (zh) * 2017-04-11 2020-06-09 江南大学 一种有降血脂作用的醋洋葱制品及制备方法
JP7099821B2 (ja) * 2017-12-20 2022-07-12 ポッカサッポロフード＆ビバレッジ株式会社 Ｐｃｓｋ９阻害剤及びコレステロール代謝改善用食品組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1714564A1 (fr) * 2005-04-21 2006-10-25 N.V. Nutricia Méthode pour le traitement ou la prévention des insuffisances respiratoires
WO2008032949A1 (fr) * 2006-09-14 2008-03-20 Ilshin Wells Co., Ltd. COMPOSITION À BASE D'HUILE GLYCÉRIDiQUE DÉRIVÉE D'HUILE DE POISSON ET SON PROCÉDÉ DE PRÉPARATION
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
WO2013192109A1 (fr) * 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Compositions d'acide pentanoïque oméga-3 et leurs procédés d'utilisation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1622467A1 (fr) * 2003-05-05 2006-02-08 Denofa AS Huiles de poisson a profil d'acides gras modifie, leur procede de production et leurs utilisations
EP1656839A1 (fr) * 2004-11-11 2006-05-17 N.V. Nutricia Nutrition contenant un mélange de lipide
CN101102988B (zh) * 2004-11-19 2011-12-14 马泰克生物科学公司 来自长链多不饱和脂肪酸的氧脂素及其制备和使用方法
WO2007058523A1 (fr) * 2005-11-17 2007-05-24 N.V. Nutricia Composition comprenant de l'acide docosapentaenoique
MX2011008448A (es) * 2009-02-10 2012-02-28 Amarin Pharma Inc Uso de ester etilico del acido eisosapentaenoico para tratar hipertrigliceridemia.
EP2405902B1 (fr) * 2009-03-09 2021-07-21 Basf As Compositions comprenant un mélange d'huile d'acide gras et d'agent tensio-actif, et leurs procédés et utilisations
EP2424521A4 (fr) * 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd Compositions pharmaceutiques comprenant de l'epa et un agent cardiovasculaire et leurs procédés d'utilisation
US20110177061A1 (en) * 2009-07-10 2011-07-21 Martek Biosciences Corporation Methods of treating and preventing neurological disorders using docosahexaenoic acid
EP2493478B8 (fr) * 2009-10-29 2018-03-28 Acasti Pharma, Inc. Compositions de phospholipides thérapeutiques concentrées
US20120302639A1 (en) * 2011-02-16 2012-11-29 Pivotal Therapeutics Inc. Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death
US8846604B2 (en) * 2011-09-02 2014-09-30 Artic Nutrition AS Lipid compositions with high DHA content

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1714564A1 (fr) * 2005-04-21 2006-10-25 N.V. Nutricia Méthode pour le traitement ou la prévention des insuffisances respiratoires
WO2008032949A1 (fr) * 2006-09-14 2008-03-20 Ilshin Wells Co., Ltd. COMPOSITION À BASE D'HUILE GLYCÉRIDiQUE DÉRIVÉE D'HUILE DE POISSON ET SON PROCÉDÉ DE PRÉPARATION
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
WO2013192109A1 (fr) * 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Compositions d'acide pentanoïque oméga-3 et leurs procédés d'utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2014143272A1 *

Also Published As

Publication number Publication date
JP2016518315A (ja) 2016-06-23
JP2016512544A (ja) 2016-04-28
WO2014143275A1 (fr) 2014-09-18
WO2014165190A2 (fr) 2014-10-09
WO2014143272A1 (fr) 2014-09-18
WO2014165190A3 (fr) 2015-01-29
EP2986148A2 (fr) 2016-02-24
CA2905795A1 (fr) 2014-10-09
WO2014158256A1 (fr) 2014-10-02
CA2905671A1 (fr) 2014-09-18
EP2968246A1 (fr) 2016-01-20

Similar Documents

Publication Publication Date Title
EP2861227A4 (fr) Compositions d'acide pentanoïque oméga-3 et leurs procédés d'utilisation
HK1213023A1 (zh) 靶向核酸的核酸的組合物和方法
IL245550A0 (en) Preparations and methods for using transposons
HK1211866A1 (en) Antioxidant compositions and methods of using the same
HK1214171A1 (zh) 賽尼克韋羅組合物及其製備和使用方法
EP3735963C0 (fr) Composition auto-émulsifiante d'acides gras oméga-3
SG11201600337PA (en) SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID
IL265876A (en) Preparations that include 15-ohepa and methods of using them
EP2953474A4 (fr) Compositions et procédés
EP2964235A4 (fr) Compositions antimicrobiennes-antibiofilm et leurs procédés d'utilisation
GB201313423D0 (en) Compositions and methods
HK1221416A1 (zh) 氧雜雙環庚烷和氧雜雙環庚烯的配製品
GB201308072D0 (en) Compositions and methods
PL2997117T3 (pl) Zastosowanie estru
SG11201602331QA (en) Compositions and methods utilizing lysophosphatidylcholine scaffolds
GB201305813D0 (en) Compositions and methods
SG11201505891VA (en) Catalyst compositions and methods of making and using same
EP2968246A4 (fr) Compositions d'acide pentanoïque oméga 3 et méthodes d'utilisation
EP2964610A4 (fr) Composition de marquage au 18f à base de vinylsulfone et procédés et utilisations associés
EP2929041A4 (fr) Compositions d'acide pentaénoïque d'oméga-3 et méthodes d'utilisation associées
IL245588A0 (en) Solid compositions of triglycerides and their use
IL240734A0 (en) Methods and compositions for preparing nucleic acids
ZA201505825B (en) Coating compositions and methods of use
GB201300628D0 (en) Compositions comprising 15-OHEPA and methods of using the same
GB201310349D0 (en) Composition and method of use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150930

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20160704

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/232 20060101ALI20160628BHEP

Ipc: A61K 31/202 20060101AFI20160628BHEP

Ipc: A61K 9/48 20060101ALI20160628BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170201